Antisense & RNAi Therapeutics Market Trends, Share | 2031

Report Description

Antisense & RNAi Therapeutics Market Outlook 2031

The global antisense & RNAi therapeutics market size was USD 3.79 Billion in 2022 and is expected to reach USD 16.89 Billion by 2031 expand at a significant CAGR 18.06% during the forecast period, 2023–2031. The growth of the market is attributed to the possibility of investigating gene function for illness management by controlling gene expression by the faulty gene, as well as R&D for the treatment of rare neurodegenerative disorders such as hereditary ATTR amyloidosis.

The therapeutic targeting of RNA is known as RNA medicine. In RNA medicine, two main techniques are used: double-stranded RNA-mediated interference (RNAi) and antisense oligonucleotides (ASO). In general, RNAi works by activating ribonucleases, which, in concert with other enzymes and complexes, coordinately breakdown the RNA once the initial RNA target has been broken into smaller pieces3.

Get Free Sample Report

Antisense oligonucleotides bind to their target nucleic acid by Watson-Crick base pairing, inhibiting or altering gene expression through steric hindrance, splicing changes, target degradation initiation, and other mechanisms. RNAi is a naturally occurring mechanism that cells employ to control gene expression and can block genes from being translated into proteins.

Furthermore, RNAi is employed in cells' innate immune response as a defensive mechanism against invading nucleic acids such as viruses and bacteria. The use of oligonucleotides to target mainly ribonucleic acids (RNA) for therapeutic purposes or in research investigations to clarify gene activities is referred to as RNA therapies.

Because of their modes of action and chemical characteristics, oligonucleotides differ from other pharmacological modalities that target primarily proteins, such as small molecules and antibodies. Deoxyribonucleic acids (DNA) and ribonucleic acids (RNA) are two types of nucleic acids (RNA). Although DNA is more durable, RNA has a wider range of structural variations, including non-coding RNAs, microRNA (miRNA), transfer RNA (tRNA), small interfering RNAs (siRNAs), ribosomal RNA (rRNA), and long-noncoding RNAs (lncRNAs). 

Researchers have attempted to target RNA as our understanding of the broad diversity of RNAs grows, since more than 80% of the genome is believed to be transcribed. Non-coding RNAs such as miRNAs and siRNAs, which play crucial roles in the transfer of genetic information from DNA to protein, the end result of the fundamental dogma in biology1, are among these transcripts.

RNA is now targeted using two methods: double-stranded RNA-mediated interference (RNAi) and antisense oligonucleotides (ASO). Both methods are now being tested in clinical trials for the treatment of RNAs implicated in illnesses including cancer and neurodegeneration.

Antisense & RNAi Therapeutics Market Trends, Drivers, Restraints, and Opportunities

• Antisense technology allows to regulate gene expression, and it's being promoted as a promising therapy for a variety of diseases this is projected to boost the market during the forecast period.
• Antisense and RNAi therapies allow for extremely precise and efficient gene silencing and a large number of gene silencing medicines are in the late stages of research are anticipated to push the market growth in the coming years.
• Increasing number of firms which are developing molecules based on antisense technology this is expected to drive the market growth during the forecast period.
• Drug delivery to the nervous tissues to pass the blood-brain barrier is anticipated to hamper the market growth during the forecast period.
• Harmful side effects caused by the use of antisense technology presents as key challenge that can hinder the market growth during the forecast period.
• Increased focus on R&D investment for development of treatment of uncommon neurodegenerative diseases, such as hereditary ATTR amyloidosis and technological advancements are expected to offer lucrative opportunities for the market players.

Scope of The Antisense & RNAi Therapeutics Market Report

The report on the global antisense & RNAi therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Antisense & RNAi Therapeutics Market Segment Insights

Antisense RNA segment is expected to account for a key share

Based on technology, the antisense & RNAi therapeutics market is bifurcated into RNA interference and antisense RNA. The RNA interference segment is further sub segmented into siRNA and miRNA. The antisense RNA segment is expected to account for a key share of the market during the forecast period owing to investigations have indicated that compounds developed using antisense technology are showing promise in the treatment of spinal muscular atrophy and amyotrophic lateral sclerosis.

Furthermore, several antisense technologies and oligonucleotide compounds are also being studied for non-neurodegenerative diseases. For example, in Duchenne muscular dystrophy, antisense-mediated exon skipping.

Get Free Sample Report

Oncology segment is expected to hold a key share

Based on application, the antisense & RNAi therapeutics market is segmented into oncology, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and other. The oncology segment is expected to hold a key share of the market during the forecast period owing to increasing need for the cure and prevention of illnesses such as cancer, HIV, and other diseases caused by mutating viruses is expected to impact oligonucleotide product usage rates.

The field of oligonucleotide medicines is rapidly developing, as seen by the growing number of clinical trials. Ionis Pharmaceuticals, for example, has four compounds in the pipeline, two of which are authorized in the European Union and one in the United States. Enzon Pharmaceuticals (Santaris Pharma), University of Texas, OncoGenex, Isarna Therapeutics, Astrazeneca (Ionis Pharmaceuticals), and INSYS Therapeutics, Inc. have a large pipeline of cancer treatments that are projected to fuel the industry.

Furthermore, several businesses have engaged in research and development for nanocarriers to transport oligonucleotides for cancer treatment, which is predicted to aid cancer management. The toxicity of these oligonucleotides can be reduced by using nanocarriers. The fact that these nanoparticle systems are impacted by inter- and intra-tumor heterogeneity is a significant bottleneck.

As a result, more efficient tumor targeting vectorization methods and multiple genes targeting oligonucleotide medicines are required. The demand for innovative and safer delivery techniques for the treatment of cancer and other viral diseases is likely to drive market expansion.

Antisense & RNAi therapeutics is expected to expand at a significant CAGR

Based on route of administration, the antisense & RNAi therapeutics market is segmented into pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, and other delivery methods. One of the most essential features of any genetically engineered molecule is the route of administration.

The effectiveness of these molecules varies depending on the route of administration, the genetically modified molecule's vector, and the type of molecule to be injected. The majority of currently ongoing research involve attenuated virus particles or bacterial cells that are administered intravenously for therapy.

One of the most essential features of any genetically engineered molecule is the route of administration. The effectiveness of these molecules varies depending on the route of administration, the genetically modified molecule's vector, and the type of molecule to be injected. The majority of currently ongoing research involve attenuated virus particles or bacterial cells that are administered intravenously for therapy.

Get Free Sample Report

North America is anticipated to dominate

On the basis of regions, the antisense & RNAi therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market CAGR during the forecast period. The regional market growth can be attributed to a number of RNAi therapies are already being developed. A number of biotechnology firms have made significant expenditures in the development of RNAi therapeutics.

Big pharmaceutical companies have gone into cooperation or license arrangements with a number of smaller companies in an attempt to profit from the projected revenue increase in this industry during the projection period. One of the key partnerships that are substantially investing in antisense technology is AstraZeneca's collaboration with Ionis Pharmaceuticals. There have been several paths of therapy development utilizing RNAi since its discovery in, however the industry has grown extremely slowly over the last decade due to the difficulties in RNAi delivery techniques.

The market has been re-infused with a significant potential for growth during the projection period due to the introduction of innovative nanotechnology-oriented approaches. A number of medication candidates now undergoing clinical trials have showed promising results and are moving forward in the development process. Assuming that such studies continue to yield favorable findings, the North American market is projected to see significant demand increase during the projection period.

Get Free Sample Report